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Summary
Objective: Magnetic resonance (MR) imaging with contrast media has shown promise for articular cartilage assessment. Dendrimer-linked
nitroxides, a new family of MR contrast agents targeted to glycosaminoglycan, may improve cartilage evaluation. This study is designed to
determine the ability of dendrimer-linked nitroxides to enhance articular cartilage and measure the intra-articular life-time of these agents.
Design: Cartilage T1 was evaluated using immature bovine patella in solutions of ﬁve different dendrimer-linked nitroxides, saline or
GdeDTPA at 1.5 T. The ‘‘relaxivity per dose’’ (change in cartilage 1/T1 produced by a given concentration of agent) was calculated. The
half-life of joint ﬂuid enhancement was measured at 2 T after solutions of three dendrimer-linked nitroxides, GdeDTPA, and saline were
injected into rabbit stiﬂe joints. Twenty-four hours after injection, the joints were examined grossly and by histology for toxicity.
Results: All but the largest dendrimer-linked nitroxide were able to intensely enhance articular cartilage on MR. Relaxivity per dose measure-
ments were between 3.5 and 68 times greater than GdeDTPA. The largest nitroxide appeared to be excluded from articular cartilage. Intra-
articular half-lives of the dendrimer-linked nitroxides were sufﬁciently long (160e208 min) for in vivo MR imaging to be performed. Histological
assessments of joints showed minimal synovial inﬂammatory and necrosis scores 1 day post-injection that were similar for all agents, includ-
ing GdeDTPA.
Conclusion: Dendrimer-linked nitroxides strongly enhance cartilage and are promising as articular cartilage-speciﬁc MR contrast agents. The
intra-articular life-time is sufﬁcient for imaging studies and, in initial evaluation, the agents exhibit minimal toxicity in rabbit joints.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis is characterized by progressive loss of articu-
lar cartilage and accompanying changes in the underlying
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815the extracellular matrix is thought to be a hallmark for early
cartilage degeneration1,2. Fissuring, ﬁbrillation and loss of
cartilage substance follow. Advances in drug development
target reversal or prevention of progression of articular car-
tilage abnormalities that begin early in the disease3,4. A sim-
ple, minimally invasive diagnostic method, which can
assess the biochemical and structural status of cartilage,
is required clinically as well as for the measurement of treat-
ment efﬁcacy.
Magnetic resonance (MR) imaging has shown great
promise for articular cartilage assessment. Numerous MR
acquisitions have been evaluated, although the majority
has focused on gross, morphologic changes rather than
early biochemical alterations5e10. The sensitivity to detect
cartilage lesions and the ability to judge the depth, or grade,
of a cartilage lesion are limited by the spatial resolution of
816 C. S. Winalski et al.: Targeted contrast agents for cartilageMR compared to the small size of early defects and ﬁs-
sures11. Addition of a contrast agent may help to identify
and grade cartilage abnormalities by increasing the MR im-
age contrast between the normal and abnormal cartilage.
For an MR contrast agent to be effective in the evaluation
of articular cartilage, it must show differential enhancement
of normal cartilage, abnormal cartilage, and joint ﬂuid. It
must also remain within the joint long enough to be imaged.
The distribution of a contrast agent between the joint ﬂuid
and articular cartilage, as with other molecules, depends
greatly on molecular charge, size, and molecular weight
(MW) of the molecule12,13. Therefore, MW and charge, in
combination with relaxivity, should determine the effective-
ness of a given dose of the agent in joint ﬂuid to effect
change in cartilage relaxation.
The equilibrium distribution of a negatively charged con-
trast agent, gadopentetate dimeglumine (GdeDTPA2)
has been shown to be inversely proportional to the negative
ﬁxed charge density (FCD) that is related to the proteogly-
can concentration8. The GdeDTPA distribution accurately
reﬂects the FCD because this small molecule is distributed
to all of the water within the cartilage. The distribution of
larger molecules is not only dependent on the molecular
charge, but also on the molecular size and amount of water
that they can access within the cartilage matrix. The proteo-
glycan and other macromolecules within the cartilage may
exclude larger molecules from portions of the matrix be-
cause of steric hindrance12. The ‘‘pore size’’ of normal car-
tilage may be smaller than these molecules and will tend to
exclude them. Since the loss of proteoglycans also incre-
ases the ‘‘pore size’’ within the matrix, the distribution of
large MW contrast agents within cartilage may offer an op-
portunity to explore other facets of cartilage degradation.
Apreviouspublicationdescribed thesynthesis of a family of
poly(propyleneimine) ‘‘DAB-type’’ dendrimers and poly(ami-
doamine) ‘‘PAMAM-type’’ dendrimers linked to stable nitro-
xides which, at physiologic pH, are positively charged and
measured their relaxivities in aqueous buffer14. Introduction
of several types of positively chargednitroxides15,16 andnitro-
xides linked to positively charged dendrimers14 into rabbit
joints showed enhancement of articular cartilage on MR im-
ages in vivo. Interestingly, the DAB-type, but not the PA-
MAM-type dendrimer-linked nitroxides enhanced the
articular cartilage14. However, there were no quantitative
measures of the ability of each compound to enhance carti-
lage and no measures of intra-articular retention of the con-
trast agents.
The current investigation builds on the previous work by
quantifying the cartilage enhancing ability of each agent
and providing preliminary data on the in vivo intra-articular
behavior in an animal model as the next step to determine
which compounds may prove useful as MR contrast
agents for cartilage evaluation. This class of dendrimeric
compounds (Fig. 1, Table I) has a range of MW and num-
ber of positive charges on each molecule at physiologic
pH17. Since the charge and molecular size inﬂuence the
distribution of the agents into cartilage and, potentially
the relaxivity of the agents in cartilage, we anticipate that
the relative abilities of each compound to enhance carti-
lage will be different than the relaxivities measured in sa-
line. For this study, three parameters felt to be critical in
clinical MR imaging of cartilage were measured for se-
lected dendrimer-linked nitroxides: (1) the relative ability
of each of the dendrimer-linked nitroxides and GdeDTPA
to shorten the cartilage spinelattice relaxation time (T1),
(2) in vivo quantiﬁcation of the half-lives of MR joint en-
hancement in a rabbit model, and (3) the acute toxicityeffects of the agents on rabbit cartilage and synovium
through histological examinations.Materials and methodsCOMPOUNDSPhysical characteristics of compounds used in this study are summarized
in Table I. 4-Trimethylaminomethyl-2,2,5,5-tetramethylpyrrolidinyloxyl iodide
[1] and dendrimer-linked nitroxides [2e6] were synthesized as described in
the literature15,17. GdeDTPA2 was obtained commercially (Magnevist,
Berlex, Wayne, NJ).IN VITRO MEASUREMENT OF CARTILAGE ENHANCEMENTMR imaging measurement of cartilage T1
MR measurements were performed for seven contrast agents in calf pa-
tellae. A total of 10 calf patellae were cut into 5 mm thick slices producing
a total of 33 samples. These samples were initially evaluated by MR imaging
in phosphate-buffered saline (PBS) at physiologic pH. Cartilage samples
from at least three patellae were then evaluated in each solution. The sam-
ples were immersed for 5 days in 40 ml of a PBS solution of either nitroxide
[1] (3.2 mM, four patellae), dendrimer-linked nitroxides [2] (0.8 mM, four pa-
tellae), [3] (0.4 mM, four patellae), [4] (0.2 mM, three patellae), [5] (0.1 mM,
three patellae), [6] (0.1 mM, three patellae) or GdeDTPA (0.1 mM, nine pa-
tellae), or PBS control (three patellae). The concentration of each paramag-
netic compound was chosen so that all solutions had similar T1 and the MR
imaging protocol would be equally sensitive to changes in T1. The samples
immersed in a PBS solution of nitroxide [5] were also measured at day 10 of
equilibration. During equilibration, the samples were kept at 4C to minimize
degradation. Vials of each solution were simultaneously imaged.
MR imaging was performed at room temperature and 1.5 T (SIGNA, Gen-
eral Electric Healthcare, Waukesha, WI) using a small volume radiofre-
quency coil (Invivo, Orlando, FL) with a single slice, fast spin echo
inversion recovery acquisition with 10 inversion times between 50 ms and
4000 ms, repetition time (TR) of 6600 ms, an echo time (TE) of 14 ms and
echo train length of 8. Field-of-view (FOV) was 10 cm 5 cm and slice thick-
ness 2 mm with a 256 128 matrix, receiver bandwidth 31 kHz, and two
signals averaged. Imaging time was 3.6 min for each acquisition. For day
10 measurements, an additional saturation recovery acquisition was per-
formed using 13 TRs between 30 and 750 ms, a bandwidth of 16 kHz,
and four signals averaged. The FOV, slice thickness, and matrix were the
same as for the inversion recovery acquisition. T1 maps were calculated
on a pixel-by-pixel basis using MATLAB (Mathworks, Natick, MA).
The cartilage T1 was measured in regions-of-interest (ROIs) selected from
the central two-thirds of the cartilage depth. For cartilage samples immersed
in a PBS solution of nitroxide [5], ROIs from the superﬁcial one-quarter of the
cartilage were also measured. The most superﬁcial and the deepest voxels
were excluded in all cases to avoid errors from partial volume averaging. The
R1dose was then calculated for each agent. ROIs from the solution vials were
also measured. For day 10 data, the T1 of the cartilage for nitroxide [5] cal-
culated from the saturation recovery measurements was used because of
the very short T1.Calculation of relaxivity per dose (R1dose)
Unlike GdeDTPA2, where the concentration of the gadolinium atom can be
measured by mass spectrometry, it is difﬁcult to measure the concentration of
dendrimer-linked nitroxides using an analytical technique, thereby making it difﬁ-
cult todetermine theT1 relaxivity incartilage,R1cart, for theseagents.Nonetheless,
the equilibrium response of cartilage relaxation rates to a given concentration of
a contrast agent in a ﬂuid bath can be used to compare the ability of these mole-
cules to enhance cartilage on MR. This measurement will be deﬁned as the
‘‘relaxivity per dose’’, R1dose.
R1dose is dependent on the distribution ratio, k, of the contrast agent be-
tween the cartilage and ﬂuid as well as R1cart as follows:
R1dose¼ R1cart  k
¼

1=T1cart withN



1=T1cart withoutN

½N fluid
where R1cart ¼ ðð1=T1cart with NÞ  ð1=T1cart without NÞÞ=½Ncart; [N]cart is
the concentration of the dendrimer-linked nitroxide, N, within cartilage;
T1cart with N is the T1 of the cartilage equilibrated in N, and T1cart without N is
the T1 of the cartilage in PBS without contrast. And k ¼ ½Ncart=½N fluid; where
[N]cart is the concentration of the dendrimer-linked nitroxide, N, within carti-
lage, and [N]ﬂuid is the concentration of N in the ﬂuid.
In this manner, R1dose is determined without knowing the concentration of
the contrast agent within the cartilage.
Fig. 1. Structures of the simple, charged nitroxide and three of the dendrimer-linked nitroxides used in this study. [1] 3-trimethylaminomethyl-
2,2,5,5-tetramethyl-1-pyrrolidinyloxyl iodide; [4] DAB-dendrimer-(NH-3-CO-PROXYL)16 with 16 nitroxides per molecule; [5] DAB-dendrimer-
(NH-3-CO-PROXYL)32 with 32 nitroxides per molecule; and [6] PAMAM-(NH-3-CO-PROXYL)32 with 32 nitroxides per molecule.
817Osteoarthritis and Cartilage Vol. 16, No. 7IN VIVO PHARMACOKINETICSAnimal protocols were approved by our Institutional Animal Care and Use
Committee. A total of 13 New Zealand white rabbits were used for this study.
The animals weighed between 3 and 4 kg. Following induction of anesthesia
by intra-muscular injection of Ketamine (40 mg/kg), Xylazine (10 mg/kg) and
Acepromazine (0.2 mg/kg), 0.5 ml of a single solution, either normal saline,
dendrimer-linked nitroxide [4] (2 mM), dendrimer-linked nitroxide [5]
(1 mM), dendrimer-linked nitroxide [6] (1 mM) or GdeDTPA (1 mM), were in-
jected into the stiﬂe (hind limb knee) joints. Both joints were imaged together
at 2 T (Biospec, Bruker Instruments, Billerica, MA) using a custom-built
12 cm quadrature radiofrequency coil. A solution standard placed next
to each stiﬂe joint was imaged simultaneously as a reference. AxialTable
Characteristics of the
Contrast agent Chemical name
GdeDTPA Gadopentetate dimeglumine
Nitroxide [1] 3-Trimethylaminomethyl-2,2,5,5-tetramethyl-1-pyrrolidiny
Nitroxide [2] DAB-dendrimer-(NH-3-CO-PROXYL)4
Nitroxide [3] DAB-dendrimer-(NH-3-CO-PROXYL)8
Nitroxide [4] DAB-dendrimer-(NH-3-CO-PROXYL)16
Nitroxide [5] DAB-dendrimer-(NH-3-CO-PROXYL)32
Nitroxide [6] PAMAM-(NH-3-CO-PROXYL)32
*From Ref. 17.
yR1ﬂuid ¼ T1 relaxivity in PBS measured at 22 C at 1.5 T14.T1-weighted images were acquired with a 10 cm FOV, 2 mm slice thickness
and 256 256 matrix with four signals averaged. The TR was 500 ms, TE
14.4 ms and imaging time 8.5 min. Images were obtained as soon as possi-
ble after injection and positioning the rabbit in the magnet (between 19 and
33 min), and every 20 min thereafter to 3 h. Mean signal intensities from
ROIs of the intra-articular ﬂuid and solution standard were measured from
each post-injection image. For each time point and each ROI, the signal in-
tensity ratio of joint ﬂuid to solution standard was calculated. We assumed
ﬁrst-order kinetics to estimate the half-life of joint ﬂuid enhancement for
each contrast agent. Signal intensities of the rabbit articular cartilage were
not measured because the number of voxels containing articular cartilage
was limited at this spatial resolution.I
contrast agents
MW
(g/mole)*,y
Theoretical
charge
(at pH 7.4)
Number of free
radicals per
molecule*
R1ﬂuidy
(s1 mM1)
548 2 e 4.76
loxyl iodide 341 1þ 1 0.18
989 2þ 4 0.78
2119 6þ 8 1.57
4378 14þ 16 2.93
8890 30þ 32 5.17
12,285 30þ 32 5.00
818 C. S. Winalski et al.: Targeted contrast agents for cartilagePRELIMINARY TOXICOLOGYThe rabbit stiﬂe joints injected above were also used for a preliminary as-
sessment of compound toxicology. After imaging, the animals moved freely
in their cages until 24 h post-dose after which they were euthanized by intra-
venous injection of an overdose of Nembutal. Both stiﬂe joints of each rabbit
were dissected and inspected visually. Samples of the synovium were har-
vested from the infrapatellar fat pad, suprapatellar recess, and adjacent to
the medial femoral condyle. Articular cartilage with attached bone was sam-
pled from the lateral trochlear margin. The tissue samples were placed in
10% phosphate-buffered formalin. Cartilage specimens were decalciﬁed in
10% formic acid in sodium citrate buffer. All samples were embedded in par-
afﬁn and cut into 5e7 mm sections. Cartilage sections were stained with
Safranin-O/fast green. The histological sections were graded by a single ob-
server with over 20 years experience in synovial and cartilage histology who
was blinded to the injected compound.
Synovial inﬂammation and necrosis were graded individually on scales
modeled after the methods described by Lindbland et al., where 0 is normal,
1 is a slight focal effect (<25% of the lining), 2 is a moderate effect (25e50%
of lining) and 3 is a severe effect on the majority of the lining18. Cartilage was
graded as follows using a variation of the Mankin scoring system: 0 is normal
articular cartilage with positive staining for Safranin-O throughout the matrix;
1 denotes small areas (<25% of the tissue section) with empty lacunae, ex-
tracellular matrix depletion and cloning; 2 indicates up to 50% of the cartilage
displaying empty lacunae and loss of extracellular matrix; and 3 denotes no
positive Safranin-O staining and damage throughout the tissue19.STATISTICAL ANALYSISChanges in T1 were analyzed for statistical signiﬁcance using a two-tailed
paired Students’ t test with a conﬁdence level of 95% (P< 0.05). All values
are reported as meanS.D.ResultsIN VITRO MEASUREMENT OF CARTILAGE ENHANCEMENTCartilage immersed inGdeDTPAand nitroxide [1] and den-
drimer-linked nitroxides [2e5] (Table I) had signiﬁcantly de-
creased T1 after 5 days (Table II). For cartilage immersed in
PBS (controls) and the largest dendrimer-linked nitroxide,
[6], we found no change (P¼ 0.5) in T1 over the equilibration
period (Fig. 2). The T1 of cartilage in GdeDTPA and nitroxide
[1] and dendrimer-linked nitroxides [2e4] were relatively uni-
formacross thecartilage fromsurface toboneonday5 indicat-
ing that equilibrium between the cartilage and solution had
beenachieved (Fig. 2). However, evenafter 10 days, cartilage
soaked in dendrimer-linked nitroxide [5] did not reach equilib-
rium (Fig. 3). The middle two-thirds of the cartilage immersed
in dendrimer-linked nitroxide [5] had an additional signiﬁcant
decrease in T1 between days 5 and 10 (P< 0.04). The T1 for
the superﬁcial one-quarter of the cartilage in dendrimer-linkedTable I
T1 values of solutions an
Contrast
solution
Contrast
concentration
(mM)
Solution T1, day 5
(msS.D.)
Cartilage T1, day 0
(msS.D.)
PBS (n¼ 3) e 2586 20 798 35
GdeDTPA (n¼ 9) 0.1 1163 60 801 50
[1] (n¼ 4) 3.2 995 90 800 45
[2] (n¼ 4) 0.8 1092 87 828 39
[3] (n¼ 4) 0.4 1020 84 840 42
[4] (n¼ 3) 0.2 1006 80 758 34
[5] (n¼ 3) 0.1 932 94 804 52
[5] (n¼ 3) 0.1 932 94 1000 171
(surface)
[6] (n¼ 3) 0.1 1067 35 710 39
*Not signiﬁcant.
yP 0.0002.
zP 0.001.
xP 0.01.nitroxide [5] also decreased slightly between days 5 and 10
although the change was not signiﬁcant (P¼ 0.1).
For negatively charged GdeDTPA, the cartilage R1dose
was 36% lower than T1 relaxivity in PBS, R1ﬂuid. (Table III).
By comparison, the positively charged nitroxide [1] and den-
drimer-linked nitroxides [2e5] had a higher cartilage R1dose
than corresponding T1 relaxivity in PBS, R1ﬂuid. Dendrimer-
linked nitroxide [6] showed no measurable enhancement
and the cartilage R1dose was much lower than R1ﬂuid in PBS.
Of the compounds [1e5], nitroxide [1] showed the least
change in cartilage relaxation rate (D1/T1cart). Dendrimer-
linked nitroxides [2e5] showed greater cartilage R1dose
than did nitroxide [1]. For each increase in size and charge
at physiologic pH of the dendrimer-linked nitroxide, there
was an increase in R1dose. Dendrimer-linked nitroxides
[3e5] had cartilage R1dose between 3.5 and 68 times
greater than GdeDTPA (Table III).IN VIVO PHARMACOKINETICSThe half-lives of joint ﬂuid enhancement by the den-
drimer-linked nitroxides were 160 47 min for dendrimer-
linked nitroxide [4], 165 17 min for dendrimer-linked
nitroxide [5] and 208 21 min for dendrimer-linked nitroxide
[6], somewhat longer than that measured for GdeDTPA at
95 16 min.PRELIMINARY TOXICOLOGYWe found minimal effects on rabbit stiﬂe joint tissues from
the injected agents at 24 h post-injection (Table IV). On gross
inspection of the joints at dissection, no differences in joint in-
ﬂammation were found in test joints compared to saline con-
trol joints. Sixteen of 26 joints (62%) appeared normal and
only a minimal inﬂammatory response was found within the
remainder. Minimal inﬂammatory response was seen in 2/4
joints injectedwith dendrimer-linked nitroxide [4], 3/7 joints in-
jected with dendrimer-linked nitroxide [5], 2/4 injected with
dendrimer-linked nitroxide [6], 2/5 injected with GdeDTPA,
and 1/6 injected with saline. While the saline group had
a lower synovial inﬂammatory score, there was no measur-
able difference between the dendrimer-linked nitroxides
and the clinically used contrast agent, GdeDTPA (Table
IV). All groups showed similar, minimal synovial necrosis
scores. There was some variability in cartilage grades,
but no measurable differences between the groups.I
d cartilage samples
Cartilage T1, day 5
(msS.D.)
Change in
Cartilage T1, day 5
(ms S.D.)
Change in cartilage
relaxation rate (D1/T1cart),
day 5 (s1S.D.)
806 48 8 18* 0.01 0.02
703 15 98 42y 0.17 0.06
415 13 385 36y 1.16 0.05
444 11 384 30y 1.04 0.03
285 42 555 11y 2.4 0.4
124 13 634 39z 6.8 0.8
274 51 530 99x 2.5 0.8
80 10
(surface)
920 181x
(surface)
11.6 2
(surface)
700 44 10 6* 0.02 0.01
Fig. 2. T1 calculated images obtained after immersion of patellar cartilage specimens in nitroxide [1], dendrimer-linked nitroxides [2e6],
GdeDTPA, or PBS bath solutions for 5 days. Cartilage T1 and R1dose values are reported below each map. Two specimens are shown for
each bath solution in the orientation depicted in the specimen photo. Cartilage (C), bone, tendon (T), and bath are identiﬁed. Lower T1 values
indicate a higher concentration of contrast agent.
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Proteoglycans within the cartilage matrix contain numer-
ous glycosaminoglycan (GAG) chains. GAG endows carti-
lage with unique biomechanical properties required for
proper joint function20. These molecules are negatively
charged at physiologic pH and are responsible for the nega-
tive FCD in cartilage. The FCD of cartilage can be estimated
through the application of Donnan theory13. According to this
theory, when cartilage is equilibrated in an ionic solution of
a small molecule, the concentration of charged ions within
the bath solution infers the concentration of charged ions
in the cartilage matrix and hence the FCD. This theory as-
sumes that the ionic molecules are distributed within all of
the cartilage water. The measurement of FCD has been
accomplished in cartilage by 23Naþ MR imaging21,22, or by
using the negatively chargedGdeDTPA2, which distributes
inversely proportional to the local FCD8.Donnan theory also predicts positively and negatively
charged contrast agents will distribute differently within car-
tilage and between cartilage and ﬂuid. For example, a con-
trast agent similar to GdeDTPA2 in all aspects, but with
a net 2þ charge rather than a 2 charge, should show
the same absolute concentration difference between re-
gions of differing GAG concentration, but with inverse distri-
bution. The same image contrast between the different
GAG concentration regions on T1-weighted images should
result from both contrast agents. However, in the case of
GdeDTPA2, regions with lower GAG concentration would
be brighter (more enhanced) than regions with higher GAG
concentration. For the agent with a þ2 charge, regions with
lower GAG concentration would be darker (less enhanced).
Donnan theory also predicts the agent with positive charge
will have a higher concentration in the articular cartilage
while the negatively charged agent would have an inversely
proportional higher concentration in the joint ﬂuid.
Fig. 3. Cartilage T1 and R1dose values of dendrimer-linked nitroxide [5] for the superﬁcial one-quarter (surface) and central two-thirds (central)
of the cartilage thickness after 5 and 10 days of equilibration in the contrast agent bath. Each T1 calculated image contains two patellar
cartilage specimens oriented as in Fig. 2. The regions outlined in white on day 10 indicate the surface ROIs.
820 C. S. Winalski et al.: Targeted contrast agents for cartilageThe relaxivity per dose,R1dose, of a contrast agent is amea-
sure of both the relaxivity of the compound within the tissue
and the distribution of the agent between the tissue and the
ﬂuid. For GdeDTPA, the cartilage R1dose was 36% of the re-
laxivity in solution. The lower cartilage R1dose of GdeDTPA
compared to its relaxivity in ﬂuid infers that GdeDTPA has
a lower concentration in normal cartilage comparedwith ﬂuid.
As expected for positively charged contrast agents, the carti-
lage R1dose for DAB-type dendrimer-linked nitroxides (Table
III) was always greater than the relaxivities in saline (R1ﬂuid).Table I
Relaxivity and relaxivity per dose for dendr
Contrast solution R1ﬂuid
(s1 mM1)
R1
(in cartilage
GdeDTPA (n¼ 9) 4.76 1.7 0.
Nitroxide [1] (n¼ 4) 0.18 0.36 0.
Nitroxide [2] (n¼ 4) 0.78 1.30 0.
Nitroxide [3] (n¼ 4) 1.57 5.9 1.
Nitroxide [4] (n¼ 3) 2.93 34 4
Nitroxide [5] (n¼ 3) 5.17 25 8
Nitroxide [5] (surface)* (n¼ 3) 5.17 116 16
Nitroxide [6] (n¼ 3) 5.00 0.2 0.
*Surface measurements were obtained from ROIs of the superﬁcial onThe ratio of cartilageR1dose toR1ﬂuid ranged from2:1 for nitro-
xide [1] to 22:1 for dendrimer-linked nitroxide [5] in the super-
ﬁcial cartilage. The greater effect of dendrimer-linked
nitroxides on cartilage T1 compared to ﬂuid is likely the result
of a higher concentration distribution of these positively
charged agents into cartilage. However, the cartilage
R1dose of the larger dendrimer-linked nitroxides is much
less than expected by Donnan equilibrium theory, based on
molecular charge. It is possible that the molecular size and
shape limit the distribution of the agents into portions of theII
imer-linked nitroxides and GdeDTPA
dose
) (s1 mM1)
R1dose
(in cartilage)/R1ﬂuid
R1dose/R1dose of
GdeDTPA
6 0.36 1
2 2.0 0.2
04 1.7 0.8
1 3.8 3.5
12 20
4.8 15
(surface) 22.4 (surface) 68 (surface)
1 0.04 0.1
e-quarter of the cartilage thickness (see Fig. 3).
Table IV
Effect of dendrimer-linked nitroxides [4], [5], and [6] on rabbit joint
tissues compared with the effects of GdeDTPA and normal saline
Intra-articular
contrast
agent
Number
of joints
Synovial
inﬂammatory
score*
Synovial
necrosis
score*
Cartilage
score*
Nitroxide [4] 4 0.4 0.3 0.4 0.2 0.9 0.7
Nitroxide [5] 7 0.4 0.2 0.4 0.2 0.8 0.4
Nitroxide [6] 4 0.4 0.3 0.5 0.2 0.3 0.2
Saline 6 0.03 0.03 0.4 0.1 0.2 0.1
GdeDTPA 5 0.2 0.1 0.5 0.2 0.0 0.0
*Data are presented as mean standard error.
821Osteoarthritis and Cartilage Vol. 16, No. 7cartilage water. Local alterations in cartilage relaxivity due to
limitedmolecularmobility in the cartilagematrix could also re-
sult in an underestimation of the cartilage concentration by
MR imaging. We could not directly measure the concentra-
tion or relaxivity of the nitroxides in the cartilage since the
electron paramagnetic resonance (EPR) spectra of these
compounds are so broad and, unlike GdeDTPA, there is
no characteristic element to bemeasured17. Thus, we cannot
determine whether the relative distribution of the nitroxides
between the ﬂuid and the cartilage or lowR1cart is responsible
for the lower than expected R1dose. Potentially, the distribu-
tion of DAB and PAMAM dendrimers into cartilage could be
analyzed by tagging the dendrimer with a chromophore or ra-
dioactive species and concentrationmeasured optically or by
scintillation counting. In spite of this limitation, data in Tables
II and III show the strong inﬂuence that the positively charged
DAB-type dendrimer-linked nitroxides have on cartilage T1.
Previous work showed that large PAMAM-type den-
drimer-linked nitroxide [6] also failed to enhance rabbit car-
tilage on MR images in an in vivo rabbit model14. Since
albumin with a MW of 67 kDa and other cationic proteins
in the range of 240e440 kDa have been shown to diffuse
into cartilage23,24, we anticipated that all of the dendrimer-
linked nitroxides, including [5] and [6], would readily distrib-
ute within this tissue. However, as shown in Fig. 3 and
Table II, dendrimer-linked nitroxide [5] failed to reach equi-
librium even at 10 days and dendrimer-linked nitroxide [6]
failed to enhance the cartilage. Since dendrimer-linked ni-
troxide [5] enhanced the superﬁcial cartilage, it is likely
that the slow enhancement equilibrium was because of
poor cartilage permeation rather than low cartilage relaxivity
in the deep zone. A low permeability of nitroxide [5] may be
attributed to molecular shape or to aggregation, as sug-
gested by Malikal et al.25. Large PAMAM-type dendrimers
linked to a different nitroxide have been shown to aggregate
in aqueous solutions26. However, molecular aggregation
has not been directly observed for the DAB-type nitroxides
[2e5] or the PAMAM-type nitroxide [6]. If aggregation of the
molecules were to occur, it would increase their effective
size and retard their diffusion into cartilage.
For an intra-articular cartilage contrast agent to be clini-
cally useful, it must remain within the joint sufﬁciently long
to perform a diagnostic MR imaging examination. We esti-
mated the intra-articular half-lives of dendrimer-linked nitro-
xides [4e6] and GdeDTPA in rabbit stiﬂe joints by
measuring the time-dependent decrease of ﬂuid signal in-
tensity on MR imaging. Dendrimer-linked nitroxides [4e6]
exhibited intra-articular half-lives somewhat greater than
the GdeDTPA and were sufﬁciently long to obtain MR im-
aging contrast changes for several hours in rabbit joints.
Examination of the rabbit stiﬂe joints for evidence of acute
toxicity showed no observable toxicity by the dendrimer-
linked nitroxides [4e6] within 1 day of injection (Table IV).With scores in this low range, variability from sampling er-
ror is expected. Synovial necrosis analysis was limited
since necrosis may not become evident on histological
examination at 24 h post-injection. Nevertheless, ﬁnding
negligible toxicity is promising for the future clinical appli-
cation of these agents for MR cartilage imaging. More
extensive measurements on these compounds are re-
quired before they can be used routinely as in vivo imag-
ing agents.
Dendrimer-linked nitroxides may prove useful for the
measurement of proteoglycan distribution as well as for im-
proved sensitivity of clinical MR images. Given the high car-
tilage R1dose for dendrimer-linked nitroxides [3e5], these
contrast agents may greatly increase the cartilage con-
trast-to-noise ratios on standard clinical MR studies and
prove useful for early disease detection, or improved quan-
titation of cartilage volumes and thicknesses for longitudinal
comparison studies. We believe this would be especially
helpful in cases where partial volume artifacts may other-
wise obscure thin cartilage regions or thin ﬁssures. Injured
or degenerated cartilage may have less steric hindrance
for large molecules within the abnormal extracellular matrix
and in areas of macroscopic fraying or ﬁbrillations23. A
greater cartilage permeation into or greater T1 relaxivity of
the high MW dendrimer-linked nitroxides within these de-
generated or ﬁbrillated regions of articular cartilage than in
normal regions of cartilage would lead to greater image
enhancement of abnormal regions. We anticipate intra-
articular application of large MW dendrimer-linked nitro-
xides would highlight the abnormal cartilage regions even
on standard, clinical MR images.
There are limitations to this study. First, the experiments
were performed on immature bovine articular cartilage in vi-
tro, and these conditions may not adequately simulate the
in vivo conditions of a human joint. Our purpose was to
compare the relative abilities of the contrast agents to en-
hance cartilage rich in GAG. The immature bovine articular
cartilage model was chosen because it was used for the
development of the delayed gadolinium-enhanced MR
imaging of cartilage (dGEMRIC) technique27, it has been
studied by MR extensively21,27e30, and it provides relatively
thick pieces of cartilage that can be imaged at 1.5 T with
minimal partial volume averaging artifacts. In comparison
with adult cartilage, immature bovine cartilage has a higher
GAG content, but the diffusion rates of water and small sol-
utes are similar21,29. Given the higher GAG content in im-
mature cartilage, the R1dose measured for the positively
charged agents in this study may be greater than would
be seen in adult cartilage. The rate of diffusion of the
dendrimer-linked nitroxides into the cut surface of the imma-
ture cartilage may have been greater than for an intact artic-
ular surface where there is a surface layer, the lamina
splendens, which may impede diffusion of larger solutes.
Swelling may have occurred in the altered cartilage used
in this experiment that could also have increased the rate
and/or amount of solute diffusion. We are currently conduct-
ing experiments with adult human cartilage to determine the
diffusion and distribution behavior of the dendrimer-linked
nitroxides in adult cartilage with an unaltered surface. Sec-
ond, we studied only normal cartilage specimens. We are
currently investigating these contrast agents in vitro in oste-
oarthritic cartilage with promising initial results31. Third, a rel-
atively small number of specimens were used in these
experiments. Our intent was to demonstrate the ability of
these new contrast agents to enhance cartilage rather
than to determine the range of variation of cartilage en-
hancement across joints and across species. Finally, only
822 C. S. Winalski et al.: Targeted contrast agents for cartilageincidental acute toxicity is presented following intra-articular
injection in rabbits as part of the study of intra-articular half-
lives. More extensive, cross species evaluation of toxicity
must be performed before these compounds can be studied
in humans.
In conclusion, we demonstrated the ability of a family of
dendrimer-linked nitroxides to enhance normal articular
cartilage in vitro. Further, we found that high MW, more pos-
itively charged nitroxides were able to more intensely
enhance the articular cartilage. The degree of enhancement
for a given dose of these dendrimer-linked nitroxides ([3e5])
was greater than for GdeDTPA. The largest, PAMAM-type
nitroxide failed to enhance the normal articular cartilage,
perhaps because relative exclusion from the cartilage or
poor cartilage relaxivity. Preliminary data suggest that,
in vivo, the intra-articular half-lives of the dendrimer-linked
nitroxides within joints are long enough for MR imaging.
On initial evaluation of joint tissues on day 1 following in-
tra-articular injection, no acute toxicity was seen.
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